EYPT
Price
$14.52
Change
+$0.83 (+6.06%)
Updated
Dec 3 closing price
Capitalization
1.2B
91 days until earnings call
Intraday BUY SELL Signals
LPCN
Price
$3.09
Change
-$0.16 (-4.92%)
Updated
Dec 3 closing price
Capitalization
17.16M
Intraday BUY SELL Signals
Interact to see
Advertisement

EYPT vs LPCN

Header iconEYPT vs LPCN Comparison
Open Charts EYPT vs LPCNBanner chart's image
EyePoint Pharmaceuticals
Price$14.52
Change+$0.83 (+6.06%)
Volume$810.49K
Capitalization1.2B
Lipocine
Price$3.09
Change-$0.16 (-4.92%)
Volume$31.25K
Capitalization17.16M
EYPT vs LPCN Comparison Chart in %
EYPT
Daily Signal:
Gain/Loss:
LPCN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
EYPT vs. LPCN commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Buy and LPCN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (EYPT: $13.69 vs. LPCN: $3.25)
Brand notoriety: EYPT and LPCN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 24% vs. LPCN: 25%
Market capitalization -- EYPT: $1.2B vs. LPCN: $17.16M
EYPT [@Biotechnology] is valued at $1.2B. LPCN’s [@Biotechnology] market capitalization is $17.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileLPCN’s FA Score has 0 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • LPCN’s FA Score: 0 green, 5 red.
According to our system of comparison, both EYPT and LPCN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 5 TA indicator(s) are bullish while LPCN’s TA Score has 5 bullish TA indicator(s).

  • EYPT’s TA Score: 5 bullish, 5 bearish.
  • LPCN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both EYPT and LPCN are a good buy in the short-term.

Price Growth

EYPT (@Biotechnology) experienced а -7.12% price change this week, while LPCN (@Biotechnology) price change was -0.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

EYPT is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($1.2B) has a higher market cap than LPCN($17.2M). EYPT YTD gains are higher at: 83.758 vs. LPCN (-33.303). LPCN has higher annual earnings (EBITDA): -5.52M vs. EYPT (-172.05M). EYPT has more cash in the bank: 256M vs. LPCN (17.9M). LPCN has less debt than EYPT: LPCN (1.48M) vs EYPT (21.8M). EYPT has higher revenues than LPCN: EYPT (51.9M) vs LPCN (4.21M).
EYPTLPCNEYPT / LPCN
Capitalization1.2B17.2M6,988%
EBITDA-172.05M-5.52M3,115%
Gain YTD83.758-33.303-252%
P/E RatioN/AN/A-
Revenue51.9M4.21M1,233%
Total Cash256M17.9M1,430%
Total Debt21.8M1.48M1,471%
FUNDAMENTALS RATINGS
EYPT vs LPCN: Fundamental Ratings
EYPT
LPCN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
70100
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
3744
P/E GROWTH RATING
1..100
1495
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LPCN's Valuation (50) in the Pharmaceuticals Other industry is in the same range as EYPT (70) in the Pharmaceuticals Major industry. This means that LPCN’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's Profit vs Risk Rating (70) in the Pharmaceuticals Major industry is in the same range as LPCN (100) in the Pharmaceuticals Other industry. This means that EYPT’s stock grew similarly to LPCN’s over the last 12 months.

LPCN's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as EYPT (98) in the Pharmaceuticals Major industry. This means that LPCN’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as LPCN (44) in the Pharmaceuticals Other industry. This means that EYPT’s stock grew similarly to LPCN’s over the last 12 months.

EYPT's P/E Growth Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for LPCN (95) in the Pharmaceuticals Other industry. This means that EYPT’s stock grew significantly faster than LPCN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTLPCN
RSI
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 7 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 7 days ago
88%
Momentum
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 7 days ago
82%
MACD
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 7 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 7 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 7 days ago
79%
Advances
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 7 days ago
84%
Declines
ODDS (%)
Bearish Trend 30 days ago
87%
Bearish Trend 15 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 7 days ago
88%
Aroon
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 7 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
EYPT
Daily Signal:
Gain/Loss:
LPCN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CFGRX57.85N/A
N/A
Commerce Growth
UMPSX53.17N/A
N/A
ProFunds UltraMid Cap Svc
MNDJX31.25N/A
N/A
MFS New Discovery R4
RGERX22.15N/A
N/A
Columbia Select Global Equity Inst2
MXVIX43.85N/A
N/A
Empower S&P 500® Index Investor

LPCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LPCN has been loosely correlated with SPRY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if LPCN jumps, then SPRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LPCN
1D Price
Change %
LPCN100%
-1.67%
SPRY - LPCN
63%
Loosely correlated
-3.88%
HYFT - LPCN
43%
Loosely correlated
-4.37%
ZNTL - LPCN
36%
Loosely correlated
-1.82%
JANX - LPCN
34%
Loosely correlated
-53.46%
EYPT - LPCN
28%
Poorly correlated
-4.00%
More